Eton Pharmaceuticals, Inc. Net Income Loss

• Eton Pharmaceuticals, Inc. showed a decrease of -20.4% in Net Income Loss from 2024 to 2025.
• This data is from Eton Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Eton Pharmaceuticals, Inc.'s Net Income Loss has grown by 63.9%.
• Historical annual values: Fiscal year 2025: -$4.60 million | Fiscal year 2024: -$3.82 million | Fiscal year 2023: -$936.0 thousand | Fiscal year 2022: -$9.02 million | Fiscal year 2021: -$1.96 million | Fiscal year 2020: -$27.97 million | Fiscal year 2019: -$18.32 million | Fiscal year 2018: -$12.74 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026